drug
fostemsavir tromethamine ER
Marketedupdated 2mo agoby ViiV Healthcare Company
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying fostemsavir tromethamine ER
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 19, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 13, 2029formulationUS 81686153.0y
- Nov 19, 2027compositionUS 77456251.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that